Rapid advancements in AI platforms and integration into business models are resulting in demand for deployed capacity, margin gains, and monetization.
Insights
With the 'Made in Italy' label under scrutiny, luxury brands are enhancing efforts on supply chain due diligence and transparency.
The tech sector today has significantly evolved from the dotcom era.
New developments around pharmaceutical tariffs and U.S. drug pricing reform suggest the hit to the biopharma industry may, over time, be less than feared.
Portfolio Manager Ollie Beckett explores how European small caps could be poised to emerge from the shadow of their large cap counterparts as Germany seeks to lead Europe’s economic resurgence.
How the continued evolution and implementation of AI is impacting companies, tech investors, and the global economy.
The risk of tariff-induced supply disruptions has raised the stakes for monetary policy error.
Risk assets rebounded in Q2 as worries about tariffs eased and earnings growth proved resilient. Can the trend continue to hold on?
AI integration and regional dynamics offer a fresh perspective for global small caps.
How pharmaceutical tariffs and drug pricing reform could help secure biopharma innovation over the long run.
In a world of constant change, the key to investment success lies in combining duration and innovation.